gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with dobutamine in 2 studies
| Studies (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Trials (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Recent Studies (post-2010) (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Studies (dobutamine) | Trials (dobutamine) | Recent Studies (post-2010) (dobutamine) |
|---|---|---|---|---|---|
| 638 | 31 | 243 | 6,357 | 818 | 1,011 |
| Protein | Taxonomy | gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate (IC50) | dobutamine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 4.17 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 5.551 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.519 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.975 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.517 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.383 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 1.944 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.599 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.966 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.383 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.114 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.895 | |
| D(3) dopamine receptor | Homo sapiens (human) | 4.985 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.155 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.518 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Block, P; De Roos, A; Dendale, P; Franken, PR; Pratikakis, Y | 1 |
| D'Amico, R; Di Girolamo, A; Ferraresi, S; Fiocchi, F; Ligabue, G; Modena, MG; Rossi, R; Sgura, F; Torricelli, P | 1 |
2 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and dobutamine
| Article | Year |
|---|---|
Contrast enhanced and functional magnetic resonance imaging for the detection of viable myocardium after infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Contrast Media; Coronary Circulation; Dobutamine; Exercise Test; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Organometallic Compounds; Prospective Studies; Sensitivity and Specificity; Thrombolytic Therapy; Tissue Survival | 1998 |
Chronic total coronary occlusion in patients with intermediate viability: value of low-dose dobutamine and contrast-enhanced 3-T MRI in predicting functional recovery in patients undergoing percutaneous revascularisation with drug-eluting stent.
Topics: Aged; Cardiotonic Agents; Chronic Disease; Contrast Media; Coronary Stenosis; Dobutamine; Drug-Eluting Stents; Female; Heterocyclic Compounds; Humans; Linear Models; Magnetic Resonance Imaging; Male; Myocardial Revascularization; Organometallic Compounds; Predictive Value of Tests; Recovery of Function; Treatment Outcome | 2009 |